- The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in second half of 2023
- Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory conditions
https://finance.yahoo.com/news/alvotech-teva-announce-acceptance-u-120000450.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.